Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects

被引:65
作者
Kast, R. E.
Foley, K. F.
机构
[1] Univ Vermont Psychiat, Burlington, VT 05401 USA
[2] Univ Vermont, Dept Med Lab & Radiat Sci, Burlington, VT USA
关键词
antinausea; antihistamine; cachexia; cancer chemotherapy; emesis; interleukin-6; mirtazapine; olanzapine; ondansetron;
D O I
10.1111/j.1365-2354.2006.00760.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mirtazapine and olanzapine are easy-to-use psychiatric drugs with potent antinausea effects. Ondansetron and later members of the 'setron class are currently standard treatments for cancer chemotherapy-related nausea and emesis. They are potent 5-HT3 blockers, but it is often not appreciated that mirtazapine and olanzapine bind with similar affinity to 5-HT3 receptors, have a longer half-life, are considerably cheaper than the 'setron class, and often offer better and smoother 24-h nausea control than'setron class drugs. Mirtazapine and olanzapine often have salutary antianxiety effects and improve sleep quality. They occasionally relieve chemotherapy-related and advanced cancer-related nausea and appetite decrease better than the 'setron group that are specifically marketed for nausea control. Mirtazapine and olanzapine frequently give potent nausea reduction and appetite increase in advanced cancer-related cachexia. Several cytokine changes potentially induced by mirtazapine and olanzapine use are discussed that may have salutary effects in several cancers. We suggest mirtazapine and olanzapine be included as first-line options in treating both chemotherapy- and advanced cancer-related nausea. Multiple clinical and economic advantages of mirtazapine and olanzapine over currently used'setron class medicines are reviewed. Double-blind studies against the 'setron class drugs are warranted.
引用
收藏
页码:351 / 354
页数:4
相关论文
共 27 条
[1]   Using histamine (H1) antagonists, in particular atypical anti psychotics, to treat anemia of chronic disease via interieukin-6 suppression [J].
Altschuler, EL ;
Kast, RE .
MEDICAL HYPOTHESES, 2005, 65 (01) :65-67
[2]  
Altschuler EL, 2005, NEW ENGL J MED, V352, P1156
[3]  
Anttila SAK, 2001, CNS DRUG REV, V7, P249
[4]   Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer [J].
Atreya, R ;
Neurath, MF .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2005, 28 (03) :187-195
[5]   TGF-β suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling [J].
Becker, C ;
Fantini, MC ;
Schramm, C ;
Lehr, HA ;
Wirtz, S ;
Nikolaev, A ;
Burg, J ;
Strand, S ;
Kiesslich, R ;
Huber, S ;
Ito, H ;
Nishimoto, N ;
Yoshizaki, K ;
Nishimoto, N ;
Galle, PR ;
Blessing, M ;
Rose-John, S ;
Neurath, MF .
IMMUNITY, 2004, 21 (04) :491-501
[6]   Olanzapine: a basic science update [J].
Bymaster, F ;
Perry, KW ;
Nelson, DL ;
Wong, DT ;
Rasmussen, K ;
Moore, NA ;
Calligaro, DO .
BRITISH JOURNAL OF PSYCHIATRY, 1999, 174 :36-40
[7]   Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine [J].
Bymaster, FP ;
Falcone, JF ;
Bauzon, D ;
Kennedy, JS ;
Schenck, K ;
DeLapp, NW ;
Cohen, ML .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 430 (2-3) :341-349
[8]   Radioreceptor binding profile of the atypical antipsychotic olanzapine [J].
Bymaster, FP ;
Calligaro, DO ;
Falcone, JF ;
Marsh, RD ;
Moore, NA ;
Tye, NC ;
Seeman, P ;
Wong, DT .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :87-96
[9]  
CIPRANDI G, 2004, ALLERGY IMMUNOL PARI, V36, P146
[10]   Interieukin-6 regulation of prostate cancer cell growth [J].
Culig, Z ;
Steiner, H ;
Bartsch, G ;
Hobisch, A .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2005, 95 (03) :497-505